SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals reports stellar Q4 numbers

09 May 2012 Evaluate

Glenmark Pharmaceuticals has reported results for fourth quarter ended March 31, 2012

The company has posted a rise of 124.97% in its net profit at Rs 148.23 crore for the quarter ended March 31, 2012 as compared to Rs 65.89 crore for the same quarter in the previous year. Total income has increased by 31.67% at Rs 502.15 crore for quarter under review as compared Rs 381.38 crore for the quarter ended March 31, 2011.

On the consolidated basis, the company has posted a rise of 32.55% in its net profit at Rs 150.35 crore for the quarter ended March 31, 2012 as compared to Rs 113.43 crore for the same quarter in the previous year. Total income has increased by 20.62% at Rs 1068.54 crore for quarter under review as compared to Rs 885.90 crore for the quarter ended March 31, 2011.

For the full year ended March 31, 2012, the company has posted a rise of 25.04% in its net profit at Rs 265.29 crore for the year ended March 31, 2012 as compared to Rs 212.17 crore for the same period in the previous year. Total income has increased by 31.19% at Rs 1619.76 crore for year under review as compared to Rs 1234.69 crore for the period ended March 31, 2011.

On the consolidated basis, the company has posted a marginal rise of 1.58% in its net profit at Rs 460.34 crore for the year ended March 31, 2012 as compared to Rs 453.20 crore for the same period in the previous year. Total income has increased by 30.56% at Rs 4038.81 crore for year under review as compared to Rs 3093.48 crore for the period ended March 31, 2011.

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×